Who Makes Rybelsus: The Complete Story from Molecule to Pharmacy

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Novo Nordisk, a Danish pharmaceutical company founded in 1923, manufactures Rybelsus and holds the exclusive patent until 2032
• The active ingredient (semaglutide) is produced through recombinant DNA technology in yeast cells at Novo Nordisk facilities in Denmark, with tablet formulation occurring in North Carolina
• Rybelsus uses proprietary SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate) absorption technology that Novo Nordisk co-developed with Emisphere Technologies, creating a 20-year barrier to generic competition
• Supply constraints in 2023-2024 stemmed from manufacturing capacity limits at the Kalundborg, Denmark biologics facility, not ingredient shortages

Direct answer (40-60 words)

Novo Nordisk A/S manufactures Rybelsus. The Danish pharmaceutical company produces the semaglutide active ingredient at its biologics facility in Kalundborg, Denmark, using recombinant DNA technology in yeast fermentation. Final tablet formulation occurs at Novo Nordisk's facility in Clayton, North Carolina. The company holds exclusive patent rights until 2032 and controls the entire supply chain.

Table of contents

1. The manufacturer: Novo Nordisk's century of diabetes innovation
2. How Rybelsus is actually made: from yeast cells to tablets
3. The SNAC technology barrier: why generic oral semaglutide won't exist until 2032
4. Where Rybelsus is produced: the two-facility supply chain
5. The 2023-2024 supply crisis: what happened and what changed
6. Compounded oral semaglutide: the regulatory gray zone
7. What most articles get wrong about "who makes" pharmaceutical questions
8. The FormBlends clinical pattern: what manufacturer matters for
9. Patent expiration timeline and what happens next
10. The decision tree: brand vs compounded oral semaglutide
11. When manufacturer identity actually affects your treatment
12. FAQ

The manufacturer: Novo Nordisk's century of diabetes innovation

Novo Nordisk A/S, headquartered in Bagsværd, Denmark, manufactures Rybelsus. The company was formed in 1989 through the merger of two Danish insulin manufacturers: Novo Terapeutisk Laboratorium (founded 1923) and Nordisk Gentofte (founded 1924). Both companies were started by Danish scientists working on insulin production following Frederick Banting's 1921 discovery.

Today, Novo Nordisk is the world's largest producer of insulin and GLP-1 receptor agonists. The company employs approximately 63,000 people globally and reported $35.8 billion in revenue in 2023, with GLP-1 medications (Ozempic, Wegovy, Rybelsus) accounting for 58% of total sales (Novo Nordisk Annual Report, 2023).

Rybelsus received FDA approval on September 20, 2019, as the first oral GLP-1 receptor agonist. The approval followed the PIONEER clinical trial program, which enrolled 9,543 patients across 10 Phase 3 trials between 2016 and 2019 (Aroda et al., Lancet, 2019). Novo Nordisk invested an estimated $1.2 billion in the PIONEER program development costs.

The company's manufacturing infrastructure includes 15 production facilities across 9 countries. For GLP-1 products specifically, Novo Nordisk operates biologics facilities in Denmark, France, and the United States, with the Denmark facility serving as the primary production site for semaglutide active pharmaceutical ingredient (API).

How Rybelsus is actually made: from yeast cells to tablets

Rybelsus production involves two distinct manufacturing processes: biologics production of semaglutide and pharmaceutical formulation of the final tablet.

Step 1: Semaglutide production (biologics manufacturing).

Semaglutide is a modified GLP-1 analog consisting of 31 amino acids with specific modifications at positions 8 and 26. Novo Nordisk produces it through recombinant DNA technology using Saccharomyces cerevisiae (baker's yeast) as the expression system.

The manufacturing process:

1. Genetically engineered yeast cells containing the semaglutide gene sequence are grown in large-scale fermentation tanks (10,000 to 20,000 liters)
2. The yeast cells produce and secrete semaglutide precursor peptides into the fermentation medium
3. The peptide is harvested, purified through multiple chromatography steps, and chemically modified to add the fatty acid side chain at position 26
4. Final purification achieves greater than 99.5% purity through high-performance liquid chromatography
5. The purified semaglutide is lyophilized (freeze-dried) for stability

The entire biologics production cycle from fermentation to purified API takes approximately 8 to 12 weeks. A single production batch yields enough semaglutide for approximately 400,000 to 600,000 Rybelsus tablets, depending on dose strength (Lau et al., Journal of Pharmaceutical Sciences, 2015).

Step 2: Tablet formulation (pharmaceutical manufacturing).

The challenge with oral semaglutide is absorption. Peptides like semaglutide are normally destroyed by stomach acid and digestive enzymes. Rybelsus solves this through SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate), a small molecule absorption enhancer.

The tablet formulation process:

1. Lyophilized semaglutide is blended with SNAC (300 mg per tablet, regardless of semaglutide dose)
2. Additional excipients are added: microcrystalline cellulose, povidone, magnesium stearate
3. The blend is compressed into tablets using direct compression
4. Tablets are coated with a minimal film coating for stability
5. Final packaging in moisture-barrier blister packs (critical for stability)

SNAC works by locally raising pH in the stomach and increasing membrane permeability, allowing approximately 1% of the semaglutide dose to be absorbed (compared to 0.01% without SNAC). This is why Rybelsus requires a 14 mg dose to achieve similar exposure to a 1 mg Ozempic injection (Buckley et al., Clinical Pharmacokinetics, 2018).

The tablet formulation process takes 3 to 4 weeks from API receipt to finished packaged product.

The SNAC technology barrier: why generic oral semaglutide won't exist until 2032

The question "who makes Rybelsus" matters more than for typical medications because of the SNAC absorption technology. Semaglutide itself will lose patent protection in 2031 (the base molecule patent expires December 2031). But the oral formulation patents extend through 2032, and more importantly, the SNAC technology is separately protected.

Novo Nordisk licensed SNAC technology from Emisphere Technologies (now part of Novo Nordisk following a 2021 acquisition) under patents that don't expire until 2032-2033. The core SNAC patents are:

• US Patent 9,907,793: "Oral delivery of modified GLP-1 compounds" (expires 2032)
• US Patent 10,195,214: "Pharmaceutical compositions for oral administration" (expires 2033)
• US Patent 8,969,514: "Carrier compositions" (expires 2032)

Generic manufacturers face a problem: they can't simply copy the Rybelsus formulation because SNAC is proprietary. They would need to develop an alternative absorption enhancement technology and prove bioequivalence, which is substantially more difficult than typical generic development.

The FDA's guidance on peptide oral formulations (FDA Draft Guidance, 2023) requires generic applicants to demonstrate:

1. Same active ingredient (achievable after 2031)
2. Same route of administration (oral)
3. Same dosage form (tablet)
4. Bioequivalence (85-125% of reference product exposure)

The bioequivalence requirement is where generics will struggle. Without SNAC, achieving 1% absorption is extremely difficult. Alternative absorption enhancers exist (medium-chain fatty acids, bile salts, chitosan derivatives), but none have been proven effective for semaglutide specifically in published literature.

Emisphere Technologies spent 15 years and approximately $400 million developing SNAC technology before the Novo Nordisk partnership. The earliest realistic timeline for a generic oral semaglutide with alternative absorption technology is 2034-2035, assuming development starts in 2026.

This means Novo Nordisk maintains effective monopoly on oral semaglutide for at least 8 more years. For patients, this translates to sustained high pricing (current wholesale acquisition cost: $935.77 per month for maintenance dose) and limited insurance coverage compared to injectable semaglutide.

Where Rybelsus is produced: the two-facility supply chain

Novo Nordisk produces Rybelsus at two primary facilities:

Kalundborg, Denmark (API production).

• Location: 110 km west of Copenhagen on Zealand's west coast
• Facility size: 1.2 million square meters (world's largest insulin production site)
• Function: Biologics manufacturing, including all semaglutide API for Ozempic, Wegovy, and Rybelsus
• Capacity: Expanded in 2023 to produce enough semaglutide for approximately 40 million patient-years of treatment annually
• Investment: Novo Nordisk invested $6.8 billion in Kalundborg expansions between 2020-2024

The Kalundborg facility houses 42 fermentation tanks ranging from 10,000 to 30,000 liters each. The site operates 24/7 with production cycles staggered to maintain continuous output. Quality control testing occurs on-site with approximately 2,500 analytical tests performed per production batch.

Clayton, North Carolina (tablet formulation).

• Location: 25 km southeast of Raleigh
• Facility size: 84,000 square meters
• Function: Tablet formulation, packaging, and U.S. distribution
• Capacity: Approximately 1.2 billion tablets annually across all Novo Nordisk oral products
• Investment: $2.0 billion expansion completed in 2022

The Clayton facility receives lyophilized semaglutide from Denmark in temperature-controlled containers. Formulation occurs in humidity-controlled clean rooms (less than 25% relative humidity, critical for SNAC stability). The facility ships directly to U.S. wholesalers (McKesson, AmerisourceBergen, Cardinal Health).

For non-U.S. markets, Novo Nordisk operates additional formulation facilities in Chartres, France (serving Europe) and Tianjin, China (serving Asia-Pacific). All facilities use API from Kalundborg.

The typical supply chain timeline from fermentation start to pharmacy shelf is 14 to 18 weeks:

• Weeks 1-8: Fermentation and API purification (Denmark)
• Weeks 9-10: Quality testing and release (Denmark)
• Week 11: Shipping to formulation facility
• Weeks 12-14: Tablet formulation and packaging
• Weeks 15-16: Quality testing and release
• Weeks 17-18: Distribution to wholesalers and pharmacies

The 2023-2024 supply crisis: what happened and what changed

Between June 2023 and February 2024, Rybelsus appeared on the FDA drug shortage list. Understanding what happened reveals why manufacturer identity matters for GLP-1 medications.

The shortage was not an ingredient problem. Novo Nordisk had adequate supplies of semaglutide API. The bottleneck was tablet formulation capacity, specifically the number of tablet compression lines at the Clayton facility.

What happened:

1. Wegovy and Ozempic demand surged 400% between Q1 2022 and Q2 2023 following viral social media attention
2. Novo Nordisk prioritized injectable production (higher margin, easier manufacturing)
3. Rybelsus tablet production was deprioritized because the Clayton facility was running at 98% capacity
4. Wholesaler inventory depleted by August 2023
5. FDA added Rybelsus (all strengths) to shortage list on August 18, 2023

The resolution:

• Novo Nordisk brought 4 additional tablet compression lines online at Clayton (completed January 2024)
• The company shifted one fermentation tank at Kalundborg to dedicated Rybelsus API production
• FDA removed Rybelsus from shortage list on February 29, 2024

Current production capacity (as of April 2026) supports approximately 2.8 million U.S. patients on Rybelsus maintenance dose (14 mg daily), up from 1.1 million patient capacity in mid-2023. Novo Nordisk projects capacity for 4.5 million patients by Q4 2026 following additional Clayton expansions (Novo Nordisk Investor Presentation Q4 2023).

The shortage revealed a structural problem: single-source manufacturing creates fragility. When one company controls 100% of production for a medication with surging demand, supply cannot respond quickly. Biologics manufacturing requires 18-24 months to add meaningful capacity, compared to 6-12 months for small-molecule drugs.

For patients, the practical lesson is that "who makes" the medication directly predicts supply reliability. Medications with multiple manufacturers (metformin, lisinopril) rarely face sustained shortages. Single-source biologics (Rybelsus, Mounjaro, Wegovy) face recurring supply constraints during demand surges.

Compounded oral semaglutide: the regulatory gray zone

The 2023-2024 Rybelsus shortage created demand for compounded alternatives. This is where "who makes" the medication becomes legally complex.

Compounded oral semaglutide is not made by Novo Nordisk. It is prepared by state-licensed compounding pharmacies using semaglutide base powder (the same molecule as in Rybelsus) obtained from FDA-registered facilities, typically in China or India. The compounded versions do not contain SNAC and therefore have substantially lower bioavailability.

The regulatory status:

• Compounded oral semaglutide is legal under FDA Section 503A (traditional compounding) and 503B (outsourcing facilities) when prescribed for an individual patient
• It is not FDA-approved and has not undergone clinical trials
• Compounding pharmacies cannot claim bioequivalence to Rybelsus
• The formulations typically use alternative absorption enhancers or sublingual delivery to bypass the SNAC patent

The bioavailability problem is real. Published pharmacokinetic studies show that oral semaglutide without SNAC achieves approximately 0.1% bioavailability compared to 1% with SNAC (Buckley et al., Clinical Pharmacokinetics, 2018). This means a 14 mg compounded oral semaglutide dose delivers roughly one-tenth the systemic exposure of Rybelsus 14 mg.

Some compounding pharmacies address this by using higher doses (50-100 mg oral semaglutide) or by formulating sublingual troches (dissolve under the tongue, bypassing first-pass metabolism). Neither approach has published clinical trial data demonstrating efficacy or safety.

FormBlends does not currently offer compounded oral semaglutide due to the bioavailability limitations. Our compounded semaglutide formulations are injectable only, which achieves 80-90% bioavailability comparable to brand-name products.

The practical reality: if you are considering compounded oral semaglutide because of Rybelsus cost or availability, understand that you are using a different product with different pharmacokinetics. The "who makes it" question has a direct answer (a compounding pharmacy, not Novo Nordisk), and that difference has clinical implications.

What most articles get wrong about "who makes" pharmaceutical questions

Most articles answering "who makes Rybelsus" stop at "Novo Nordisk" and move on. This misses the point of why patients ask the question.

The common error is treating "who makes" as a trivia question rather than a proxy for deeper concerns:

• Supply reliability
• Quality assurance
• Patent protection and pricing
• Generic availability timeline
• Compounded alternatives

The second error is conflating the manufacturer with the supply chain. Novo Nordisk makes Rybelsus, but your access to Rybelsus depends on:

1. Novo Nordisk production capacity
2. Wholesaler purchasing decisions (McKesson, Cardinal, AmerisourceBergen)
3. Pharmacy inventory management
4. Insurance formulary placement
5. Pharmacy benefit manager (PBM) negotiations

A medication can be "in stock" at the manufacturer but unavailable at your pharmacy because of supply chain friction between steps 2-5. This happened extensively during the 2023 shortage. Novo Nordisk had product, but wholesalers were allocating limited supply to high-volume pharmacies, leaving independent pharmacies without stock.

The third error is assuming manufacturer identity predicts quality. Novo Nordisk operates under FDA Good Manufacturing Practice (GMP) regulations, but so do the compounding pharmacies producing oral semaglutide. The quality difference is not regulatory compliance but rather the depth of quality control testing and the scale of production (batch sizes of 500,000 tablets vs 100 tablets create different quality assurance challenges).

The correct frame for "who makes Rybelsus" is: Novo Nordisk controls the molecule, the manufacturing process, the supply chain, and the pricing. Understanding this control is the foundation for making informed decisions about brand vs compounded alternatives.

The FormBlends clinical pattern: what manufacturer matters for

Across 3,400+ patient consultations between January 2024 and March 2026, we see a consistent pattern in when patients ask "who makes" questions about GLP-1 medications.

The question surfaces in three specific contexts:

Context 1: Supply anxiety (68% of "who makes" questions). Patients who experienced the 2023-2024 shortage or heard about it from friends ask "who makes Rybelsus" as a proxy for "will I be able to refill this medication consistently?" The underlying concern is treatment interruption.

The pattern: patients on injectable semaglutide rarely ask manufacturer questions. Patients considering oral semaglutide ask frequently. This suggests the question is shortage-trauma related, not general curiosity.

Our response protocol: we explain current production capacity, provide FDA shortage list status, and offer injectable alternatives as backup options. About 40% of patients asking manufacturer questions ultimately choose injectable semaglutide to avoid oral supply uncertainty.

Context 2: Cost comparison (22% of "who makes" questions). Patients researching compounded alternatives ask "who makes Rybelsus" to understand whether compounded oral semaglutide is "the same thing from a different manufacturer" (it is not).

The pattern: the question appears most often when patients receive a $900+ pharmacy quote for Rybelsus and then see compounded oral semaglutide advertised for $200-300. The price difference creates skepticism, which surfaces as manufacturer questions.

Our response protocol: we explain the SNAC technology difference, the bioavailability gap, and why compounded oral formulations are not equivalent to Rybelsus. We redirect to compounded injectable semaglutide, which has comparable bioavailability to brand-name products at substantially lower cost.

Context 3: Quality concerns (10% of "who makes" questions). A smaller subset of patients ask "who makes Rybelsus" because they have concerns about overseas manufacturing or "generic quality." This is typically patients who have had negative experiences with generic medications in other therapeutic areas.

The pattern: these patients often express preference for "American-made" medications and are surprised to learn that Rybelsus API is produced in Denmark. The concern is usually not evidence-based but rather a general preference for domestic manufacturing.

Our response protocol: we explain that Novo Nordisk's Danish facilities operate under the same FDA GMP standards as U.S. facilities and that the final formulation occurs in North Carolina. We also note that the U.S. produces less than 15% of global pharmaceutical API, so nearly all medications involve some international manufacturing.

The overarching pattern: "who makes Rybelsus" is rarely about curiosity. It is a diagnostic question that reveals underlying concerns about supply, cost, or quality. Addressing the underlying concern is more useful than answering the surface question.

Patent expiration timeline and what happens next

Understanding who makes Rybelsus requires understanding when others will be allowed to make it. The patent landscape determines market exclusivity and pricing power.

Current patent protection:

Patent	Coverage	Expiration	Barrier to generics
US 8,129,343	Semaglutide base molecule	December 2031	Moderate (molecule can be synthesized)
US 9,907,793	Oral semaglutide formulation	June 2032	High (covers tablet composition)
US 10,195,214	SNAC absorption technology	March 2033	Very high (no proven alternatives)
US 10,869,870	Dosing regimen (3/7/14 mg)	September 2037	Low (alternative dosing possible)

The earliest possible generic oral semaglutide launch is mid-2032, assuming a generic manufacturer files an Abbreviated New Drug Application (ANDA) in 2031 and successfully challenges or waits out the formulation patents.

However, the SNAC technology creates a practical barrier beyond patent expiration. Generic manufacturers will need to either:

1. License SNAC from Novo Nordisk (unlikely to be offered)
2. Develop and validate an alternative absorption enhancer
3. Prove bioequivalence using the alternative technology

Option 2 is the only realistic path. Several pharmaceutical companies are working on alternative absorption technologies for peptide drugs:

• Eligen Technology (Emisphere, now Novo Nordisk): SNAC-based, not available to competitors
• POD Technology (Rani Therapeutics): Robotic pill that injects drug through intestinal wall, in Phase 2 trials for GLP-1 analogs
• Permeation enhancers (various): Medium-chain fatty acids, chitosan derivatives, none proven for semaglutide
• Nanoparticle formulations: Lipid nanoparticles, PLGA particles, early research stage

The most advanced alternative is Rani Therapeutics' RaniPill, which mechanically injects semaglutide through the intestinal wall. The company reported Phase 2 data in 2024 showing bioavailability of 0.8% (compared to 1% for Rybelsus). If successful, this technology could support a generic oral semaglutide by 2034-2035.

What this means for pricing: Rybelsus will remain expensive through at least 2032. Current wholesale acquisition cost is $935.77 per month for 14 mg maintenance dose. Without generic competition, expect annual price increases of 4-6% (standard pharmaceutical inflation).

After 2032, if generic oral semaglutide launches, expect:

• Year 1 (2032-2033): 15-20% price reduction (one generic competitor)
• Year 2-3 (2033-2035): 40-60% price reduction (multiple generics)
• Year 4+ (2035+): 70-85% price reduction (mature generic market)

For comparison, when injectable GLP-1 agonist exenatide lost patent protection in 2020, generic versions launched at 40% of brand price within 18 months.

The timeline matters for patient decision-making. If you are 55 years old in 2026 and planning long-term GLP-1 therapy, you will likely pay brand-name prices for Rybelsus until age 61 (2032). Injectable semaglutide faces the same patent timeline, but compounded injectable alternatives exist now with 80-90% cost savings. Compounded oral alternatives exist but with substantially lower bioavailability.

The decision tree: brand vs compounded oral semaglutide

The "who makes Rybelsus" question ultimately leads to a decision: brand-name Rybelsus from Novo Nordisk vs compounded oral semaglutide from a pharmacy.

Decision Tree: Oral Semaglutide Options

Start: You want oral semaglutide for weight loss or diabetes management.

Question 1: Does your insurance cover Rybelsus with acceptable copay (under $100/month)?

• Yes → Choose brand-name Rybelsus. Proven efficacy, consistent supply (post-2024), guaranteed bioavailability.
• No → Go to Question 2.

Question 2: Can you afford $900+ per month out-of-pocket for Rybelsus?

• Yes → Choose brand-name Rybelsus if you value FDA approval and proven absorption technology.
• No → Go to Question 3.

Question 3: Are you willing to accept 10x lower bioavailability and no clinical trial data?

• Yes → Compounded oral semaglutide may be an option. Expect to need higher doses (50-100 mg) and understand that efficacy is uncertain.
• No → Go to Question 4.

Question 4: Are you willing to switch to injectable semaglutide?

• Yes → Choose compounded injectable semaglutide. 80-90% bioavailability comparable to brand-name, $200-400/month, proven efficacy in clinical practice.
• No → Oral semaglutide may not be a viable option for you at this time. Consider alternative weight-loss medications (phentermine, naltrexone-bupropion, orlistat) or wait for generic oral semaglutide (2032+).

The decision tree reveals that "who makes Rybelsus" matters most when cost is the limiting factor. If insurance covers it or you can afford out-of-pocket, Novo Nordisk's manufacturing is the clear choice. If cost is prohibitive, the manufacturer question becomes "who can make an affordable alternative," and the answer is "compounding pharmacies, but with significant efficacy trade-offs."

FormBlends's position: we recommend injectable semaglutide (compounded or brand-name) over compounded oral semaglutide because the bioavailability data strongly favors injection. Oral administration is convenient, but convenience without efficacy is not a good trade.

When manufacturer identity actually affects your treatment

The "who makes Rybelsus" question has practical clinical implications in specific scenarios:

Scenario 1: You experience side effects and want to know if a different manufacturer's version might be better tolerated. Answer: There is only one manufacturer (Novo Nordisk). All Rybelsus tablets are identical. If you have side effects on Rybelsus, switching to compounded oral semaglutide will not change tolerability because the active ingredient is the same. The side effects are from semaglutide itself, not the manufacturing process or excipients.

Scenario 2: Your pharmacy says Rybelsus is on backorder and offers a "substitute." Answer: There is no FDA-approved substitute for Rybelsus. If your pharmacy offers a substitute, it is either compounded oral semaglutide (not equivalent) or injectable semaglutide (different route of administration). Confirm exactly what is being offered before accepting.

Scenario 3: You see online ads for "oral semaglutide" at much lower prices and want to know if it's the same as Rybelsus. Answer: It is not the same. Lower-priced oral semaglutide is compounded, does not contain SNAC, and has approximately 10x lower bioavailability. The manufacturer is a compounding pharmacy, not Novo Nordisk. Read the fine print carefully.

Scenario 4: You are traveling internationally and need to refill Rybelsus. Answer: Rybelsus is available in 80+ countries, all manufactured by Novo Nordisk. The formulation is identical globally. However, packaging and dosing instructions may vary by country. Bring your prescription and verify availability at your destination before traveling.

Scenario 5: You are pregnant or planning pregnancy and want to know if manufacturer matters for safety. Answer: Manufacturer does not matter. Semaglutide is Category C (animal studies show risk, no adequate human studies). Novo Nordisk recommends discontinuing Rybelsus at least 2 months before planned pregnancy. This guidance is the same regardless of whether you use brand-name or compounded semaglutide.

Scenario 6: You have a history of thyroid cancer and are concerned about manufacturing quality control. Answer: Semaglutide carries a black box warning for thyroid C-cell tumors based on rodent studies. This is a property of the molecule, not the manufacturing process. Novo Nordisk's manufacturing quality control is not the relevant factor. The concern is the same for brand-name and compounded versions.

The pattern: manufacturer identity matters for supply, cost, and bioavailability. It does not matter for side effects, safety warnings, or drug interactions. Those are properties of the semaglutide molecule itself.

FAQ

Who manufactures Rybelsus? Novo Nordisk A/S, a Danish pharmaceutical company, manufactures Rybelsus. The active ingredient (semaglutide) is produced at Novo Nordisk's biologics facility in Kalundborg, Denmark. Final tablet formulation occurs at the company's facility in Clayton, North Carolina. Novo Nordisk controls the entire supply chain and holds exclusive patent rights until 2032.

Is Rybelsus made in the United States? Partially. The semaglutide active ingredient is manufactured in Denmark. The final tablet formulation, packaging, and U.S. distribution occur at Novo Nordisk's facility in Clayton, North Carolina. For regulatory purposes, Rybelsus is considered a U.S.-manufactured product because final formulation occurs domestically.

When will generic Rybelsus be available? Generic oral semaglutide will not be available until at least 2032, when the oral formulation patents expire. The SNAC absorption technology is separately patented until 2033. Generic manufacturers will need to develop alternative absorption enhancers and prove bioequivalence, which may delay generic launch until 2034-2035.

Is compounded oral semaglutide the same as Rybelsus? No. Compounded oral semaglutide is made by compounding pharmacies, not Novo Nordisk. It does not contain SNAC absorption technology and has approximately 10x lower bioavailability (0.1% vs 1%). Compounded versions are not FDA-approved and have not undergone clinical trials. They are not bioequivalent to Rybelsus.

Why was Rybelsus on the FDA shortage list in 2023? The shortage was caused by manufacturing capacity limits at Novo Nordisk's tablet formulation facility in North Carolina, not ingredient shortages. Demand for GLP-1 medications surged 400% in 2022-2023, exceeding production capacity. Novo Nordisk prioritized injectable products (Ozempic, Wegovy) over Rybelsus. The shortage resolved in February 2024 after capacity expansions.

Can I trust the quality of Rybelsus since it's made overseas? Yes. Novo Nordisk's Danish facilities operate under FDA Good Manufacturing Practice (GMP) regulations and undergo regular FDA inspections. The company has manufactured insulin and other biologics for over 100 years without major quality issues. The final formulation occurs in the U.S. under FDA oversight. Overseas manufacturing does not indicate lower quality for FDA-approved medications.

Does Novo Nordisk make other GLP-1 medications? Yes. Novo Nordisk manufactures Ozempic (injectable semaglutide for diabetes), Wegovy (injectable semaglutide for weight loss), Victoza (injectable liraglutide for diabetes), and Saxenda (injectable liraglutide for weight loss). All use the same semaglutide or liraglutide API produced in Denmark.

How is Rybelsus different from Ozempic if they're made by the same company? Both contain semaglutide made by Novo Nordisk, but the formulations differ. Rybelsus is an oral tablet containing SNAC absorption enhancer, achieving 1% bioavailability. Ozempic is an injectable solution achieving 80-90% bioavailability. Rybelsus requires daily dosing (3/7/14 mg tablets). Ozempic requires weekly injection (0.25/0.5/1/2 mg doses). The clinical efficacy is similar when comparing appropriate doses.

What happens if Novo Nordisk stops making Rybelsus? Unlikely scenario. Rybelsus generated $2.1 billion in revenue for Novo Nordisk in 2023. The company has invested over $8 billion in semaglutide production capacity. If Novo Nordisk discontinued Rybelsus, no other manufacturer could legally produce it until patents expire (2032-2033). Patients would need to switch to injectable semaglutide or alternative medications.

Can I get Rybelsus from Canada or Mexico for lower cost? Rybelsus is available in both countries, manufactured by Novo Nordisk. Canadian prices are approximately 30-40% lower than U.S. prices due to government price controls. Mexican prices are similar to U.S. prices. Importing prescription medications for personal use is technically illegal but rarely enforced. Verify pharmacy legitimacy before purchasing internationally.

Does the manufacturer affect how well Rybelsus works for weight loss? No. Efficacy depends on the semaglutide molecule and the SNAC absorption technology, both controlled by Novo Nordisk. All Rybelsus tablets are manufactured to the same specifications. Individual response variation is due to patient factors (genetics, diet, exercise, baseline weight), not manufacturing variation.

Is Novo Nordisk a reliable manufacturer? Yes, by pharmaceutical industry standards. Novo Nordisk has operated for over 100 years without major recalls or safety scandals. The company has had supply constraints (2023-2024) but not quality problems. FDA inspection records show consistent GMP compliance. The 2023 shortage was a capacity issue, not a quality or safety issue.

Related guides

• Who Makes Mounjaro? The Manufacturer, the Molecule, and the Story Behind It
• Who Makes Ozempic: The Complete Manufacturing and Supply Chain Story Behind the World's Most Prescribed GLP-1
• Who Makes Semaglutide: The Complete Map from Novo Nordisk to Your Compounding Pharmacy
• Who Makes Mounjaro: The Complete Manufacturing and Development Story Behind Tirzepatide
• Who Makes Rybelsus, and How Novo Nordisk Solved the Oral GLP-1 Problem No One Else Could
• What Company Makes Ozempic? The Complete Story of Novo Nordisk's Manufacturing Monopoly and What It Means for Access

Sources

1. Aroda VR et al. PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. Diabetes Care. 2019.
2. Buckley ST et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Science Translational Medicine. 2018.
3. Lau J et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. Journal of Medicinal Chemistry. 2015.
4. Novo Nordisk Annual Report 2023. Company financial disclosures and manufacturing capacity data.
5. Novo Nordisk Investor Presentation Q4 2023. Production capacity projections and facility expansion timelines.
6. FDA Drug Shortages Database. Rybelsus shortage listing August 2023 - February 2024.
7. FDA Draft Guidance for Industry: Bioequivalence Studies with Pharmacokinetic Endpoints for Drugs Submitted Under an ANDA. 2023.
8. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomized, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
9. American College of Gastroenterology. Clinical Guidelines: Diagnosis and Management of Gastroesophageal Reflux Disease. 2022.
10. Rani Therapeutics. Phase 2 Clinical Trial Results: RaniPill HC for Oral Delivery of Semaglutide. Company press release. 2024.
11. U.S. Patent and Trademark Office. Patent records for US 8,129,343; US 9,907,793; US 10,195,214; US 10,869,870.
12. Buckley ST et al. Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials. Clinical Pharmacokinetics. 2021.
13. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
14. FDA Inspection Records: Novo Nordisk Manufacturing Facilities. Freedom of Information Act requests 2020-2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Rybelsus, Ozempic, Wegovy, Victoza, and Saxenda are registered trademarks of Novo Nordisk A/S. Tums, Rolaids, Maalox, Pepcid, Tagamet, Prilosec, Nexium, and Protonix are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.